{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:23:49Z","timestamp":1783117429635,"version":"3.54.6"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016802","name":"Natural Science Foundation of Changzhou Municipality","doi-asserted-by":"publisher","award":["kq2202405"],"award-info":[{"award-number":["kq2202405"]}],"id":[{"id":"10.13039\/100016802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["20201179"],"award-info":[{"award-number":["20201179"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600183"],"award-info":[{"award-number":["81600183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070175"],"award-info":[{"award-number":["82070175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30830"],"award-info":[{"award-number":["2022JJ30830"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ70058"],"award-info":[{"award-number":["2022JJ70058"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.heliyon.2023.e18836","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:25:09Z","timestamp":1690838709000},"page":"e18836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphoma"],"prefix":"10.1016","volume":"9","author":[{"given":"Shicong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.heliyon.2023.e18836_bib1","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.3390\/curroncol28060456","article-title":"Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma","volume":"28","author":"Mohammed Saleh","year":"2021","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e18836_bib2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e18836_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e18836_bib4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e18836_bib5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/jat.3961","article-title":"Benzene and its effects on cell signaling pathways related to hematopoiesis and leukemia","volume":"40","author":"Lu","year":"2020","journal-title":"J. Appl. Toxicol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e18836_bib6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cas.13393","article-title":"Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma","volume":"109","author":"Fukumoto","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2023.e18836_bib7","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.2147\/CMAR.S185030","article-title":"Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"15","key":"10.1016\/j.heliyon.2023.e18836_bib8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e18836_bib9","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"De Leval","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e18836_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41375-021-01321-2","article-title":"High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)","volume":"36","author":"Pritchett","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e18836_bib11","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/s41467-018-04608-8","article-title":"Exploring patterns enriched in a dataset with contrastive principal component analysis","volume":"9","author":"Abid","year":"2018","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e18836_bib12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e18836_bib13","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e18836_bib14","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e18836_bib15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat. Genet."},{"issue":"7041","key":"10.1016\/j.heliyon.2023.e18836_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature03555","article-title":"A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity","volume":"435","author":"Vinuesa","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e18836_bib17","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2011-07-365130","article-title":"Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice","volume":"120","author":"Ellyard","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e18836_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2023.e18836_bib19","article-title":"HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e18836_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.leukres.2015.12.006","article-title":"The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation","volume":"41","author":"Wampfler","year":"2016","journal-title":"Leuk. Res."},{"issue":"7689","key":"10.1016\/j.heliyon.2023.e18836_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nature25193","article-title":"A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies","volume":"553","author":"Bahr","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e18836_bib22","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2015-207701","article-title":"Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases","volume":"75","author":"Rusmini","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e18836_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/cei.12407","article-title":"MEFV gene polymorphisms and TNFRSF1A mutation in patients with inflammatory myopathy with abundant macrophages","volume":"178","author":"Fujikawa","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.heliyon.2023.e18836_bib24","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3389\/fgene.2019.01063","article-title":"The role of tumor microenvironment in genomic instability of malignant tumors","volume":"10","author":"Sonug\u00fcR","year":"2019","journal-title":"Front. Genet."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e18836_bib25","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e18836_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e18836_bib27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.heliyon.2023.e18836_bib28","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e18836_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020888","article-title":"Pathological mechanisms of bortezomib-induced peripheral neuropathy","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e18836_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bjh.14505","article-title":"The combination of bortezomib with chemotherapy to treat relapsed\/refractory acute lymphoblastic leukaemia of childhood","volume":"176","author":"Bertaina","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e18836_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17460441.2017.1268596","article-title":"The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma","volume":"12","author":"Arkwright","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.heliyon.2023.e18836_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine-induced peripheral neuropathy: a mini-review","volume":"81","author":"Li","year":"2020","journal-title":"Neurotoxicology"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e18836_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900320","article-title":"Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations","volume":"353","author":"He","year":"2020","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e18836_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051135","article-title":"Dinaciclib, a bimodal agent effective against endometrial cancer","volume":"13","author":"Howard","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e18836_bib35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/gutjnl-2019-320441","article-title":"CDK1\/2\/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer","volume":"70","author":"Huang","year":"2021","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e18836_bib36","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1002\/cam4.2324","article-title":"Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway","volume":"8","author":"Zhao","year":"2019","journal-title":"Cancer Med."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e18836_bib37","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1182\/bloodadvances.2019000064","article-title":"Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia","volume":"3","author":"Yun","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e18836_bib38","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdy336","article-title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","volume":"29","author":"Piotrowska","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e18836_bib39","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.3109\/10428194.2014.995647","article-title":"AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-\u03baB activation","volume":"56","author":"Tsai","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e18836_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00280-020-04201-1","article-title":"A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma","volume":"87","author":"Murray Stewart","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"22","key":"10.1016\/j.heliyon.2023.e18836_bib41","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1182\/blood.2021013901","article-title":"Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression","volume":"139","author":"Cao","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e18836_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-16-1140","article-title":"Biphasic rapamycin effects in lymphoma and carcinoma treatment","volume":"77","author":"Liu","year":"2017","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.heliyon.2023.e18836_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184474","article-title":"Second generation mTOR inhibitors as a double-edged sword in malignant glioma treatment","volume":"20","author":"Heinzen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e18836_bib44","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1038\/s41467-021-27197-5","article-title":"Interleukin-7 receptor \u03b1 mutational activation can initiate precursor B-cell acute lymphoblastic leukemia","volume":"12","author":"Almeida","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2023.e18836_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/870918","article-title":"Activity of BKM120 and BEZ235 against lymphoma cells","volume":"2015","author":"Civallero","year":"2015","journal-title":"BioMed Res. Int."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023060449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023060449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:52:37Z","timestamp":1783115557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023060449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2405844023060449"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18836","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e18836"}}